Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
TVTXTravere Therapeutics(TVTX) ZACKS·2024-08-02 08:00

For the quarter ended June 2024, Travere Therapeutics (TVTX) reported revenue of 54.12million,down9.454.12 million, down 9.4% over the same period last year. EPS came in at -0.90, compared to -1.13intheyear−agoquarter.ThereportedrevenuecomparestotheZacksConsensusEstimateof1.13 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of 49.5 million, representing a surprise of +9.33%. The company delivered an EPS surprise of -3.45%, with the consensus EPS estimate being -$0.87.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings - ...